A study to evaluate the food effect on drug availability, pharmacokinetic (PK) properties, safety and tolerability of two different dose combination therapy of saxagliptin/dapagliflozin/metformin extended-release (XR) against individual component co-administration.

Trial Identifier: D168AC00001
Sponsor: AstraZeneca
NCTID:: NCT03169959
Start Date: May 2017
Primary Completion Date: August 2017
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, MD Baltimore, MD, United States of America, 21225